vir-2218
Nucleic acidexperimental
Clinical trial activity
17 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
15
Phase 3
2
Phase 4
0
Earliest trial started Oct 31, 2018 (NCT03672188)
Timeline
Indications
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5315044 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07142811 | Phase 2 | Aug 5, 2025 | Vir Biotechnology, Inc. |
| NCT07128550 | Phase 3 | Jul 30, 2025 | Vir Biotechnology, Inc. |
| NCT06903338 | Phase 3 | Mar 12, 2025 | Vir Biotechnology, Inc. |
| NCT06650852 | Phase 2 | Nov 30, 2024 | Brii Biosciences |
| NCT06491563 | Phase 2 | Aug 31, 2024 | Brii Biosciences, Vir Biotechnology, Inc. |
| NCT06092333 | Phase 2 | Jan 3, 2024 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT05970289 | Phase 2 | Aug 22, 2023 | Brii Biosciences, Vir Biotechnology, Inc. |
| NCT05844228 | Phase 1 | Jun 1, 2023 | Vir Biotechnology, Inc. |
| NCT05612581 | Phase 1/Phase 2 (Phase 2) | Nov 9, 2022 | Vir Biotechnology, Inc. |
| NCT05484206 | Phase 1 | Sep 21, 2022 | Vir Biotechnology, Inc. |
| NCT05461170 | Phase 2 | Sep 17, 2022 | Vir Biotechnology, Inc. |
| NCT04891770 | Phase 2 | Aug 14, 2021 | Gilead Sciences, Vir Biotechnology, Inc. |
| NCT04856085 | Phase 2 | Jul 11, 2021 | Vir Biotechnology, Inc. |
| NCT04749368 | Phase 2 | Apr 12, 2021 | Brii Biosciences, VBI Vaccines Inc., Vir Biotechnology, Inc. |
| NCT04507269 | Phase 2 | Aug 18, 2020 | Alnylam Pharmaceuticals, Brii Biosciences, Vir Biotechnology, Inc. |
| NCT04412863 | Phase 2 | Jun 30, 2020 | Alnylam Pharmaceuticals, Vir Biotechnology, Inc. |
| NCT03672188 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2018 | Alnylam Pharmaceuticals, Vir Biotechnology, Inc. |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vir Biotechnology, Inc. | For profit | 15 | 10 | 3 | 2018 |
| Brii Biosciences | For profit | 5 | 5 | 1 | 2020 |
| Alnylam Pharmaceuticals | For profit | 3 | 0 | 1 | 2018 |
| Gilead Sciences | For profit | 1 | 1 | 1 | 2021 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 1 | 1 | 2024 |
| VBI Vaccines Inc. | For profit | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1